Do your own DD.
USRM's response was after the letter. As important RMAT would be, that is not the reason for the run up to .10. The company changed it's entire business model last year and the rise to at least .10 was based on elimination of toxic debt, creating income, growing the business, and teaming up with others to make up for business weaknesses that were there. I know this because I have been here since 3 days before the stock rose from .002 to .04. The rise from .10 to .17 can be attributed at least in part, to RMAT. Now we have Texas RTT as a work around of the FDA's RMAT, so if it doesn't happen, it is no longer a problem. Check out what they are doing for ED, COPD, knee replacements, cancer, shoulders, elbows... This is a $100 billion industry and USRM is leading the way.
News 
Market Data 
Discover 
